Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Hansen, Bo F ^a   Glendorf, Tine ^a   Hegelund, Anne C ^a   Lundby, Anders ^a   Lützen, Anne ^a   Slaaby, Rita ^a   Stidsen, Carsten Enggaard ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN RECEPTOR; INSULIN RECEPTOR A; INSULIN RECEPTOR B; INSULIN X10; LONG ACTING DRUG; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; LONG ACTING INSULIN; LR(3)IGF I; LR(3)IGF-I; SOMATOMEDIN C;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME PHOSPHORYLATION; HUMAN; LIGAND BINDING; MITOGENICITY; NONHUMAN; PHARMACOLOGICAL STIMULATION; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; MITOSIS; PHOSPHORYLATION; PROTEIN BINDING;

CELLS, CULTURED; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; INSULIN, REGULAR, HUMAN; INSULIN-LIKE GROWTH FACTOR I; MITOSIS; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, IGF TYPE 1;

EID: 84860688139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034274     Document Type: Article

References (35)

1. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, et al. (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52 (9): 1732-1744.
2. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52 (9): 1755-1765.
3. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, et al. (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52 (9): 1745-1754.
4. Currie CJ, Poole CD, Gale EA, (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52 (9): 1766-1777.
5. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, et al. (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33 (9): 1997-2003.
6. Pocock SJ, Smeeth L, (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374: 511-513.
7. Pollak M, Russell-Jones D, (2010) Insulin analogues and cancer risk: cause for concern or cause célèbre? Int J Clin Pract 64 (5): 628-636.
8. Drejer K, (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8: 259-285.
9. Hansen BF, Kurtzhals P, Boisen Jensen A, Dejgaard A, Russell-Jones D, (2011) Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 2011 54 (9): 2226-31.
10. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjørn S, et al. (1991) Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40 (11): 1488-1495.
11. Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, Skottner A, et al. (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34 (5): 307-313.
12. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R, (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18 (1): 19-25.
13. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, et al. (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49 (6): 999-1005.
14. Hansen BF, Danielsen GM, Drejer K, Sørensen AR, Wiberg FC, et al. (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1;315(Pt 1): 271-279.
15. Hansen BF, (2008) Insulin analogues with increased mitogenic potency- are they safe? Horm Metab Res 40 (6): 431-433.
16. Bonnesen C, Nelander GM, Hansen BF, Jensen P, Krabbe JS, et al. (2010) Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin. Cell Biol Toxicol 26 (4): 293-307.
17. Slaaby R, Schäffer L, Lautrup-Larsen I, Andersen AS, Shaw AC, et al. (2006) Hybrid Receptors Formed by Insulin Receptor (IR) and Insulin-like Growth Factor 1 Receptor (IGF-1R) Have Low Insulin and High IGF-1 Affinity Irrespective of the IR Splice Variant. J Biol Chem 281: 25869-25874.
18. Soos MA, Siddle K, Baron MD, Heward JM, Luzio JP, et al. (1986) Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. Biochem J 235: 199-208.
19. Soos MA, Field CE, Lammers R, Ullrich A, Zhang B, et al. (1992) A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding and biological activity. J Biol Chem 267: 12955-12963.
20. Glendorf T, Sørensen AR, Nishimura E, Pettersson I, Kjeldsen T, (2008) Importance of the solvent-exposed residues of the insulin B chain alpha-helix for receptor binding. Biochemistry 47 (16): 4743-4751.
21. European Pharmacopoeia, (2008) Statistical analysis of results of biological assays and tests. 6th edition. Strasbourg, France European Directorate for the Quality of Medicines.
22. Vølund A, (1978) Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models. Biometrics 34 (3): 357-365.
23. Sommerfeld MR, Müller G, Tschank G, Seipke G, Habermann P, et al. (2010) In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One 4; 5 (3): e9540.
24. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, et al. (2010) Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 53 (12): 2667-2675.
25. Varewijck AJ, Goudzwaard JA, Brugts MP, Lamberts SW, Hofland LJ, et al. (2010) Insulin glargine is more potent in activating the human IGF-1 receptor than human insulin and insulin detemir. Growth Horm IGF Res 20 (6): 427-431.
26. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, et al. (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocrine-Related Cancer 16: 429-441.
27. Sørensen AR, Stidsen CE, Ribel U, Nishimura E, Sturis J, et al. (2010) Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Diabetes Obes Metab 12: 665-673.
28. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H, (2009) Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25 (1): 41-49.
29. Kazda C, Slieker L, Ilag L, Byrd R, Rees T, et al. (2010) Appraising the mitogenicity of insulin analogues relative to human insulin-response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activity in cultured cancer cells. Diabetes Metab Res Rev 25(1): 41-49. Diabetes Metab Res Rev 26 (3): 145-149.
30. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, et al. (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53 (8): 1743-1753.
31. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R, (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30 (6): 586-623.
32. Glendorf T, Stidsen CE, Norrman M, Nishimura E, Sørensen AR, et al. (2011) Engineering of insulin receptor isoform-selective insulin analogues. PLoS One 6 (5): e20288.
33. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, et al. (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277: 39684-39695.
34. Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, et al. (1997) Insulin receptor IGF-1 receptor hybrids are widely distributed in mammalian-tissues- quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochemical J 327: 209-215.
35. Eckardt K, May C, Koenen M, Eckel J, (2007) IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50: 2534-2543.